March 2026
M	T	W	T	F	S	S
	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

Akinchan Bhardwaj: The Real Silent Shift in the 2026 ACC/AHA Dyslipidemia Guideline

Akinchan Bhardwaj/LinkedIn

Mar 21, 2026, 15:36

Akinchan Bhardwaj: The Real Silent Shift in the 2026 ACC/AHA Dyslipidemia Guideline

Akinchan Bhardwaj, Consultant Interventional Cardiologist at Kauvery Hospital, shared a post on LinkedIn:

“Everyone is talking about LDL targets in the new 2026 ACC/AHA Dyslipidemia guideline.

The bigger story is that the guideline changes how we think about risk.

For years, much of lipid decision-making in primary prevention was dominated by a 10-year risk frame.

Now the conversation is clearly moving toward something more biologically honest: atherosclerosis is not just about short-term event prediction.

It is about cumulative exposure to atherogenic particles over time.

That shift shows up in several places in the new ACC guideline:

stronger emphasis on treating dyslipidemia earlier to reduce lifelong exposure burden
use of the PREVENT equations instead of the older pooled cohort equations for 10- and 30-year risk assessment in adults 30 to 79 years
explicit attention to young adults with LDL-C more than/equal 160 mg/dL or a strong family history of premature ASCVD
and yes, the return of LDL-C and non-HDL-C treatment goals alongside percentage reduction

That is an update beyond just a technical update.

Because many patients do not become ‘high risk’ suddenly at age 55.
They spend years, sometimes decades, accumulating risk quietly.
By the time the 10-year risk estimate becomes impressive, the biology may have been active for a long time.

That is why I think this guideline matters beyond the headline changes.

It nudges us to think less like emergency responders to future events and more like clinicians managing lifetime plaque exposure.

Interestingly, the ESC guidelines update (2025) was already very much aligned with a goal-based, intensive lipid-lowering mindset, with emphasis on LDL-C lowering strategies, Lp(a), hypertriglyceridaemia and special populations.

In that sense, ACC now feels closer to the biology-first direction Europe has been pushing.

For me, the practical message is simple:

we should stop thinking only in terms of ‘Who is high risk today?’ and start thinking more often in terms of ‘Who is accumulating vascular injury already?’

That is where earlier prevention becomes more meaningful.

And that may be the real silent shift in this guideline.”

Akinchan Bhardwaj: The Real Silent Shift in the 2026 ACC/AHA Dyslipidemia Guideline